FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other Drugs
The Pharma Data
NOVEMBER 23, 2021
The study compared the two groups’ plasma CMV DNA concentration levels at the end of the study’s eighth week, with efficacy defined as having a level below what is measurable. Livtencity may reduce the antiviral activity of ganciclovir and valganciclovir, so coadministration with these drugs is not recommended. Source link: [link].
Let's personalize your content